Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Queensland Health
Daiichi Sankyo
US Army

Generated: November 23, 2017

DrugPatentWatch Database Preview

Details for Patent: RE39221

« Back to Dashboard

Summary for Patent: RE39221

Title:Composition comprising a tramadol material and acetaminophen and its use
Abstract:This invention relates to a composition comprising a tramadol material and acetaminophen, and its use. As used herein tramadol refers to various forms of tramadol. The compositions are pharmacologically useful in treating pain and tussive conditions. The compositions are also subject to less opioid side-effects such as abuse liability, tolerance, constipation and respiratory depression. Furthermore, where the components of the compositions are within certain ratios the pharmacological effects of the compositions are superadditive (synergistic).
Inventor(s): Raffa; Robert B. (Norristown, PA), Vaught; Jeffrey L. (Glenmoore, PA)
Assignee: Ortho-McNeil Pharmaceutical, Inc. (Raritan, NJ)
Application Number:10/761,096
Patent Claim Types:
see list of patent claims
Composition; Use; Dosage form; Formulation;

No matches for this query

International Patent Family for Patent: RE39221

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria169498► Subscribe
Australia2579992► Subscribe
Australia651247► Subscribe
Canada2095523► Subscribe
China1071571► Subscribe
China1086133► Subscribe
Germany122004000032► Subscribe
Germany69226624► Subscribe
Denmark0566709► Subscribe
European Patent Office0566709► Subscribe91079Luxembourg► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School
Boehringer Ingelheim
Federal Trade Commission

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus